Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

Contributed by: Business Wire

Tags

Health
Health Technology
Genetics
Research
Science
Pharmaceutical
Biotechnology
Broken String Biosciences

More Like This

Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations

PR Newswire associated0

The World's First Clinical Base Edting Therapy for Hemoglobinopathy

Business Wire logo

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

(Graphic: Business Wire)

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication

ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

CRISPR-Ready ioGlutamatergic Neurons (Graphic: Business Wire)

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery